Euclidean Technologies Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Euclidean Technologies Management’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$194K	Hold	18,475	–	–	0.18%	70
2022 Q4	$229K	Hold	18,475	–	–	0.22%	56
2022 Q3	$191K	Hold	18,475	–	–	0.21%	61
2022 Q2	$213K	Hold	18,475	–	–	0.22%	63
2022 Q1	$232K	Hold	18,475	–	–	0.21%	66
2021 Q4	$215K	Hold	18,475	–	–	0.18%	80
2021 Q3	$241K	Hold	18,475	–	–	0.21%	59
2021 Q2	$238K	Buy	+18,475	New	+$211K	0.19%	63

Other funds holding IRWD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Euclidean Technologies Management's IRWD Position: Q1 2023 in Review

Euclidean Technologies Management held its Ironwood Pharmaceuticals (IRWD) position steady in Q1 2023 at 18,475 shares worth $194K. The position accounts for 0.18% of the portfolio, ranked #70.

Euclidean Technologies Management first reported a position in IRWD in Q2 2021 and has held it in 8 quarters since. The position peaked at $241K in Q3 2021. 254 funds tracked by Wall St. Rank hold IRWD as of Q1 2023.

Euclidean Technologies Management held 18,475 shares of Ironwood Pharmaceuticals worth $194K as of Q1 2023.
Euclidean Technologies Management left its Ironwood Pharmaceuticals share count unchanged in Q1 2023.
Ironwood Pharmaceuticals made up 0.18% of Euclidean Technologies Management's portfolio in Q1 2023, its #70 holding.
Euclidean Technologies Management first reported a position in Ironwood Pharmaceuticals in Q2 2021 and has held it in 8 quarters since.
Euclidean Technologies Management's Ironwood Pharmaceuticals position peaked at $241K in Q3 2021.
254 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2023.

Based on Euclidean Technologies Management's 13F filing for Q1 2023, filed 26 Apr 2023.